| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.094 | 0.003 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.003 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.51 | 0.003 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.097 | 0.003 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.005 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | 0.093 | 0.006 |